Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Catechin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 4/20 | 0.97 |
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 0.97 |
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.97 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | ALPL | P05186 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | BACE1 | P56817 | 6/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.97 |
| ▸ | SNCA | P37840 | 5/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.97 |
| ▸ | MAPT | P10636 | 4/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.97 |
| ▸ | APEX1 | P27695 | 3/20 | 0.97 |
| ▸ | RECQL | P46063 | 3/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
| ▸ | PKM | P14618 | 2/20 | 0.97 |
| ▸ | RAD52 | P43351 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (-)-Catechin SCHEMBL31239761 | 1.00 | KDM4E (1.00) | KDM4EGAAALPLPOLBBACE1 | |
| Catechin SCHEMBL2701497 | 1.00 | KDM4E (1.00) | KDM4EGAAALPLPOLBBACE1 | |
| Catechin SCHEMBL10805275 | 1.00 | KDM4E (1.00) | KDM4EGAAALPLPOLBBACE1 | |
| Cianidanol SCHEMBL29377426 | 1.00 | KDM4E (1.00) | KDM4EGAAALPLPOLBBACE1 | |
| Cianidanol SCHEMBL133974 | 1.00 | KDM4E (1.00) | KDM4EGAAALPLPOLBBACE1 | |
| Cianidanol SCHEMBL23754693 | 1.00 | KDM4E (1.00) | KDM4EGAAALPLPOLBBACE1 | |
| Cianidanol SCHEMBL29394049 | 1.00 | KDM4E (1.00) | KDM4EGAAALPLPOLBBACE1 | |
| Cianidanol SCHEMBL2701496 | 1.00 | KDM4E (1.00) | KDM4EGAAALPLPOLBBACE1 | |
| Cianidanol SCHEMBL19741 | 0.99 | BACE1 (1.00) | KDM4EGAAALPLPOLBBACE1 | |
| (+)-Epicatechin SCHEMBL862089 | 0.99 | BACE1 (1.00) | KDM4EGAAALPLPOLBBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260061091-A1 | MUSSEL-INSPIRED TISSUE ADHESIVES AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2026-03-05 | — | — | US | claimed |
| EP-4572812-A2 | MUSSEL-INSPIRED TISSUE ADHESIVES AND METHODS OF USE THEREOF | Purdue Research Foundation (US) | 2025-06-25 | — | — | EP | claimed |
| CN-119744184-A | Mussel inspired tissue adhesives and methods of use thereof | 普渡研究基金会 | 2025-04-01 | — | — | CN | claimed |
| WO-2024096656-A1 | PHARMACEUTICAL COMPOSITION INCLUDING CATECHIN HYDRATE AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 경북대학교 산학협력단 | 2024-05-10 | — | — | WO | claimed |
| WO-2024040270-A2 | MUSSEL-INSPIRED TISSUE ADHESIVES AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2024-02-22 | — | — | WO | claimed |
| CN-115814146-B | Preparation method of hemostatic powder with bionic coagulation mechanism | 山东大学 | 2023-12-22 | — | — | CN | claimed |
| US-20230272232-A1 | Low Temperature Antioxidant Reductant for Copper Nanoparticles | NNSA | 2023-08-31 | — | — | US | claimed |
| CN-110857214-B | Method for preparing low-sensitivity copper azide by compounding rGO and copper nanowire | 南京理工大学 | 2023-08-22 | — | — | CN | claimed |
| CN-115814146-A | Preparation method of hemostatic powder for bionic blood coagulation mechanism | 山东大学 | 2023-03-21 | — | — | CN | claimed |
| WO-2022225060-A1 | METHOD FOR SUPPRESSING PRODUCTION OF DEGRADATION PRODUCTS | 協和キリン株式会社 | 2022-10-27 | — | — | WO | claimed |
| WO-2009136408-A1 | SYNERGISTIC PHARMACEUTICAL COCRYSTALS | INSTITUTE OF LIFE SCIENCES (IN) | 2009-11-12 | — | — | WO | claimed |
| WO-2009082735-A1 | MELANINS SYNTHESIZED CHEMICALLY OR VIA ENZYME CATALYSIS | UNIVERSITY OF CHICAGO (US) | 2009-07-02 | — | — | WO | claimed |
| WO-2008153945-A2 | NUTRACEUTICAL CO-CRYSTAL COMPOSITIONS | UNIVERSITY OF SOUTH FLORIDA (US) | 2008-12-18 | — | — | WO | claimed |
| US-7396895-B2 | Branched polyarylene ethers and processes for the preparation thereof | XEROX CORPORATION (US) | 2008-07-08 | — | — | US | claimed |
| EP-1877422-A1 | GREEN TEA POLYPHENOL ALPHA SECRETASE ENHANCERS AND METHODS OF USE | UNIVERSITY OF SOUTH FLORIDA (US) | 2008-01-16 | — | — | EP | claimed |
| WO-2006116535-A1 | GREEN TEA POLYPHENOL ALPHA SECRETASE ENHANCERS AND METHODS OF USE | UNIVERSITY OF SOUTH FLORIDA (US) | 2006-11-02 | — | — | WO | claimed |
| US-7067608-B2 | Process for preparing branched polyarylene ethers | XEROX CORPORATION (US) | 2006-06-27 | — | — | US | claimed |
| US-20050208416-A1 | Branched polyarylene ethers and processes for the preparation thereof | XEROX CORPORATION | 2005-09-22 | — | — | US | claimed |
| US-20050154178-A1 | Process for preparing branched polyarylene ethers | XEROX CORPORATION | 2005-07-14 | — | — | US | claimed |
| EP-0087164-B1 | NOVEL CRYSTAL MODIFICATIONS, PROCESSES FOR THEIR PRODUCTION, AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | Zyma SA (CH) | 1987-05-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061091-A1 | MUSSEL-INSPIRED TISSUE ADHESIVES AND METHODS OF USE THEREOF | CDH1, EPCAM, KEAP1 | PTGS1 1040/4885MEN1 501/4885PTGS2 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.